A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

BCR-ABL1-STAT5 is an oncogenic signaling pathway in human chronic myelogenous leukemia (CML) and it represents a valid target for anti-CML drug design. Resistance to direct BCR-ABL1 inhibitors is a common clinical issue, so STAT5 inhibition has become an interesting alternative target. In this study...

Full description

Bibliographic Details
Main Authors: Patricia Martín-Rodríguez, Borja Guerra, Idaira Hueso-Falcón, Haidee Aranda-Tavío, Juan Díaz-Chico, José Quintana, Francisco Estévez, Bonifacio Díaz-Chico, Angel Amesty, Ana Estévez-Braun, Leandro Fernández-Pérez
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Pharmacology
Subjects:
leukemia
imatinib
BCR-ABL1
drug resistance
naphthoquinone
coumarin
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01546/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01546/full

Similar Items